Both Innodata and Innovent Biologics rose by around +11%, and Shopify also rose by about eight percentage points: Innodata secured a new Big Tech contract worth $51 million, and its pivot to AI data infrastructure is supported by its second-largest client in quantitative terms; Shopify is following the recovery narrative of the SaaS sector and AI recommendations, with no specific catalyst; Innovent Biologics is rebounding with the overall sentiment of the Hong Kong stock innovative drug sector this week.
The nature of the three driving forces is different: Innodata's story relies on order fulfillment, Shopify leans towards valuation repair, and Innovent Biologics is more like a sector sentiment rebound. To distinguish which can continue, the focus should be on Innodata's Q2 customer concentration disclosure and Innovent's clinical progress.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
